Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...910111213141516171819...208209»
  • ||||||||||  Review, Journal:  Clinical overview of trophoblast surface antigen 2 antibody-drug conjugates in non-small cell lung cancer. (Pubmed Central) -  Feb 9, 2026   
    TROP2 ADCs have shown antitumor responses with a manageable safety profile in patients with mNSCLC in several ongoing and completed trials. Additional studies are required to understand how these agents can be effectively integrated into the treatment paradigm for lung cancer, taking into consideration sequential use of multiple ADCs, resistance mechanisms, combination therapies, and use in special populations.
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
    Trial completion, Trial completion date, Trial primary completion date:  SHR-A1811-I-102: A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors (clinicaltrials.gov) -  Feb 7, 2026   
    P1,  N=101, Completed, 
    TACE-TKI-Tisle offers balanced efficacy and safety, while TACE-TKI-Tori provides notable OS benefits, warranting further validation in prospective studies. Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Mar 2025
  • ||||||||||  THE EFFICACY AND SAFETY OF PD-1 MONOCLONAL ANTIBODY IN THE TREATMENT OF HEMOPHAGOCYTIC SYNDROME:SYSTEMATIC REVIEW (ePoster Area) -  Feb 7, 2026 - Abstract #EBMT2026EBMT_1721;    
    This study is the first to demonstrate that hetrombopag significantly accelerates neutrophil and platelet engraftment in auto-HSCT patients compared to eltrombopag. Data regarding the efficacy and safety of PD-1 monoclonal antibodies used (such as sintilimab, nivolumab, camrelizumab, and tislelizumab) in both pediatric and adult patients with HLH were included...In pediatric patients (aged 3
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Journal, PD(L)-1 Biomarker, IO biomarker:  CD8-Guided Immunochemotherapy Improves Pathological Complete Response Rates in High Tumor Burden Triple-Negative Breast Cancer. (Pubmed Central) -  Feb 5, 2026   
    Multi-omics analyses demonstrated significantly elevated CD8+T-cell infiltration in camrelizumab-treated pCR patients, alongside strong correlations between PD-L1 expression, stromal tumor-infiltrating lymphocytes (sTILs), and CD8+ density. These results indicate that CD8-guided immunochemotherapy with camrelizumab improves pCR rates in high tumor burden TNBC with manageable toxicity, supporting CD8+ T-cell levels as a predictive biomarker for immunotherapy response.
  • ||||||||||  rivocibart (SHR-1918) / Jiangsu Hengrui Pharma
    Trial completion:  Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia (clinicaltrials.gov) -  Feb 5, 2026   
    P2,  N=44, Completed, 
    These results indicate that CD8-guided immunochemotherapy with camrelizumab improves pCR rates in high tumor burden TNBC with manageable toxicity, supporting CD8+ T-cell levels as a predictive biomarker for immunotherapy response. Active, not recruiting --> Completed
  • ||||||||||  AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
    Adebrelimab plus chemotherapy (chemo) as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC): 5-year update of the phase III CAPSTONE-1 study (Foyer) -  Feb 5, 2026 - Abstract #ELCC2026ELCC_724;    
    P3
    Pts were given four to six cycles of carboplatin (area under the curve of 5 mg/mL per min on day 1 of each cycle) and etoposide (100 mg/m2 of body-surface area on days 1 Here, we report updated outcomes 5 yrs after enrollment of the last patient.Methods Patients with previously untreated ES-SCLC were randomized 1:1 to receive 4-6 cycles of adebrelimab (20 mg/kg, iv, d1, q3w) or placebo, with carboplatin (AUC 5, d1, q3w) plus etoposide (100 mg/m2, d1, d2, d3, q3w), followed by maintenance therapy with adebrelimab or placebo.
  • ||||||||||  AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
    Adebrelimab combined with definitive concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer: A single-arm, exploratory phase II study (Foyer) -  Feb 5, 2026 - Abstract #ELCC2026ELCC_617;    
    P4
    The most common grade 3-4 treatment-related adverse events were decreased lymphocyte count(Seven [26%] of 27 patients), decreased neutrophil count (four [15%]). Treatment-related serious adverse events occurred in 2 (6%) of 27 patients, which included infusion reactions (1 [3%]), pneumonitis (1 [3%]).Conclusions Adebrelimab combined with concurrent chemoradiotherapy demonstrated remarkable efficacy and tolerable toxicity in patients with unresectable stage III non-small cell lung cancer, and these findings warrant further validation in large-sample studies.
  • ||||||||||  ruzaltatug rezetecan (SHR-A2009) / Jiangsu Hengrui Pharma
    SHR-A2009, a HER3-targeted ADC, in advanced solid tumors: Updates from a phase I study (Foyer) -  Feb 5, 2026 - Abstract #ELCC2026ELCC_377;    
    P1, P3
    Based on balanced efficacy and safety, 8.0 mg/kg was selected as RP3D for SHR-A2009 monotherapy. A randomized phase III trial (NCT06671379) comparing SHR-A2009 with PBC is ongoing in pts with EGFR-mutated NSCLC progressing after EGFR-TKI.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, albendazole / Generic mfg.
    Preclinical, Journal:  Effect of apatinib on albendazole metabolism in vitro and in vivo. (Pubmed Central) -  Feb 4, 2026   
    For the metabolites albendazole sulfoxide and hydroxyalbendazole, apatinib caused significant increases in AUC(0-t), AUC(0-?), and Tmax, while a significant decrease in CLz/F. In summary, apatinib could inhibit the metabolism of albendazole in vitro and in vivo, so albendazole should be closely monitored for adverse effects when used in combination with apatinib and discontinued if necessary.
  • ||||||||||  Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, AiTan (rivoceranib) / HLB Bio Group, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Review, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker:  Case report: Immune checkpoint inhibitor-induced fulminant diabetic ketoacidosis: a case-based review and considerations for immunotherapy discontinuation. (Pubmed Central) -  Feb 4, 2026   
    This case demonstrates that while ICIs can provide exceptional long-term benefits in advanced NSCLC, particularly in patients with highly immunogenic mutation profiles, they may also trigger late-onset fatal irAEs. Our findings underscore the imperative for close, long-term metabolic surveillance throughout the course of immunotherapy, regardless of treatment duration or radiological stability.
  • ||||||||||  AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
    Trial primary completion date, Real-world evidence:  Dalpiciclib in HR+/HER2- ABC (clinicaltrials.gov) -  Feb 4, 2026   
    P=N/A,  N=103, Recruiting, 
    These findings support hetrombopag plus CsA as a potential first-line therapeutic intervention for NSAA, especially in TD-NSAA patients. Trial primary completion date: Dec 2025 --> Jan 2027
  • ||||||||||  rivocibart (SHR-1918) / Jiangsu Hengrui Pharma
    Trial completion, Trial primary completion date:  Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic (clinicaltrials.gov) -  Feb 3, 2026   
    P2,  N=335, Completed, 
    Trial primary completion date: Dec 2025 --> Jan 2027 Active, not recruiting --> Completed | Trial primary completion date: Oct 2024 --> Jul 2025